CYCN · As filed with the SEC
Korsana Biosciences cash flow statement, by fiscal year
The statement as Korsana Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
| Net loss | (3,528,000) | (3,057,000) | (5,263,000) | (44,078,000) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Gain from settlement of account payable | 0 | (363,000) | — | — |
| Share-based compensation expense | 441,000 | 625,000 | 1,067,000 | 6,252,000 |
| Gain on disposal of discontinued operations | — | 0 | (15,752,000) | — |
| Depreciation and amortization | — | — | 0 | 65,000 |
| Impairment loss | — | 0 | 3,304,000 | — |
| Net loss on disposal of property and equipment | — | — | — | 0 |
| Loss on lease termination | — | — | — | 0 |
| Gain on extinguishment of debt | — | — | — | 0 |
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | (444,000) | (556,000) | 96,000 | 4,000 |
| Related party accounts receivable | — | — | — | 0 |
| Prepaid expenses | 37,000 | 21,000 | 363,000 | 123,000 |
| Other current assets | 5,000 | (5,000) | 160,000 | (69,000) |
| Operating lease assets | — | 0 | 108,000 | 184,000 |
| Other assets | — | 0 | 213,000 | 366,000 |
| Accounts payable | 118,000 | (445,000) | (1,772,000) | 1,142,000 |
| Related party accounts payable | — | — | — | 0 |
| Accrued research and development costs | 146,000 | (38,000) | (2,185,000) | (4,078,000) |
| Operating lease liabilities | — | — | — | 0 |
| Accrued expenses and other current liabilities | (89,000) | (515,000) | (1,584,000) | (522,000) |
| Net cash used in operating activities | (3,314,000) | (4,333,000) | (21,245,000) | (40,611,000) |
| Net proceeds from disposal of discontinued operations | — | 0 | 10,402,000 | — |
| Purchases of property and equipment | — | — | — | 0 |
| Proceeds from sale of property and equipment | — | — | — | 0 |
| Net cash provided by investing activities | — | 0 | 10,402,000 | 0 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
| Proceeds from equity private placement and ATM | — | — | — | 0 |
| Proceeds from ATM | 2,077,000 | — | — | — |
| Proceeds from private placement | 1,375,000 | 0 | 5,000,000 | — |
| Proceeds from exercises of stock options and ESPP | — | 0 | 24,000 | 29,000 |
| Issuance costs paid for private placement | (130,000) | — | — | — |
| Net cash provided by financing activities | 3,322,000 | 0 | 5,024,000 | 29,000 |
| Effect of exchange rate changes on cash and cash equivalents | 0 | (6,000) | 8,000 | 3,000 |
| Net increase (decrease) in cash and cash equivalents | 8,000 | (4,339,000) | (5,811,000) | (40,579,000) |
| Cash and cash equivalents, beginning of period | 3,232,000 | 7,571,000 | 13,382,000 | 53,961,000 |
| Cash and cash equivalents, end of period | 3,240,000 | 3,232,000 | 7,571,000 | 13,382,000 |
| Non-cash gain on disposal of discontinued operations | — | 0 | 5,350,000 | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.